Photo by jrkorpa from unsplash
An experimental drug has been found to cut the number of menopausal hot flushes by almost three quarters in an early trial reported in the Lancet .1 The trial, funded… Click to show full abstract
An experimental drug has been found to cut the number of menopausal hot flushes by almost three quarters in an early trial reported in the Lancet .1 The trial, funded by the UK Medical Research Council and the National Institute for Health Research, tested a neurokinin 3 receptor antagonist (MLE4901), originally developed by AstraZeneca and licensed to Millendo Therapeutics, in women who experienced severe flushing as a menopausal symptom. Postmortem studies of brain tissue from post-menopausal women have shown that it contains elevated levels of neurokinin B, and researchers at Imperial College London …
Journal Title: British Medical Journal
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!